CATALYSTYahoo Finance • 19h ago
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?Yahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
Why SDGR Stock dropped -9.50% Today — RQD Quant Desk Flash
$27.14 -9.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $26.62
Schrodinger Inc. (SDGR) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $2.03B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SDGR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Schrodinger Inc. (NASDAQ: SDGR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $27.14 (-9.50% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SDGR ranks #231 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SDGR compare to MRVI and ZYME in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SDGR leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SDGR?
▼
Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $26.62 (-1.90%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SDGR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY SDGR SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)
Altman Z-Score 2.64 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$25.89-9.6% Next Q
45
Q2 (-2Q)Grade D$23.40+14.2% Next Q
48
Q3 (-1Q)Grade C-$26.72+1.6% Next Q
50
CurrentGrade D+$27.14-0.9% Hist 90D α
53
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SDGR Turnaround Squeeze
While SDGR currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.33) and Max Pain ($28.50) forces dealer call-delta covering toward $35.47.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SDGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SDGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SDGR Stock dropped -9.50% Today — RQD Quant Desk Flash
Schrodinger Inc. (SDGR) dropped -9.50% to $27.14, trading at 71% of its 52-week range ($10.94 – $33.78). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 71% of its 52-week range ($10.94 – $33.78) with RSI-14 at 51.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $27.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 55.7% gross margin and $12.5M annual free cash flow.
Live SDGR Headlines & Catalysts
MARKET WIREStockInvest.us • 22h ago
Schrodinger Stock Price Forecast. Should You Buy SDGR?StockInvest.us report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Schrodinger Inc (SDGR) Stock Down 11.3% but Still Overvalued -- GF Score: 71/100GuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI GrowthYahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Up to 40% of lithium ions in battery fluid cluster. This could help guide battery design.Stock Titan report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Is Schrödinger (SDGR) Fully Valued As Analyst Upgrades Back Its AI Drug Discovery Story?Simply Wall St report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
How Schrodinger Inc. (SDGR) Affects Rotational Strategy TimingStock Traders Daily report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHGuruFocus • 1d ago
Schrodinger Inc (SDGR) Shares Fall 5.0% -- What GF Score of 72 TGuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4d ago
iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?IRHYTHM HLDGS (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREYahoo • 5d ago
Schrödinger (SDGR) Stock Sees Fair Value Lift As AI Optimism Lifts Analyst TargetsSchrödinger’s updated fair value estimate has moved from US$22.29 to US$25.86, which points to a higher price target in the latest round of analyst work. Recent commentary links this shift to growing interest in AI drive
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SDGR)
- ✓Walkthrough of SDGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SDGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +110.39%▲ ASCENDING CHANNEL
2026-11-03O $29.99H $29.99L $27.14C $27.14VOL 1.95M
RES: $37.70SUP: $19.12SMA50: $25.33SMA200: $16.87
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SDGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +23.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SDGR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SDGR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SDGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SDGR)
Health Care Rank #231 of 1016
⚔️ MRVI vs SDGR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SDGR vs. MRVI, ZYME, SEPN, SRPT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Schrodinger Inc. (SDGR) ranks #231 by composite RQD confidence (53/100, grade D+) and #252 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, SDGR leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with SDGR at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SDGR
ACTIVE
Schrodinger Inc. | D+ | 53/100 | — | 55.7% | -35.0% | -9.50% | $2.03B | Benchmark Subject |
| MRVI Maravai LifeSciences Holdings Inc. (Class A) | D- | 37/100 | — | 18.3% | -35.0% | -7.68% | $2.03B | /mrvi-vs-sdgr → |
| ZYME Zymeworks Inc. | D | 50/100 | — | — | -32.2% | -0.35% | $2.02B | /zyme-vs-sdgr → |
| SEPN Septerna Inc. | C | 63/100 | — | — | -20.7% | -2.72% | $2.05B | /sepn-vs-sdgr → |
| SRPT Sarepta Therapeutics Inc. | E | 27/100 | — | 96.0% | -35.0% | -3.17% | $1.97B | /srpt-vs-sdgr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001490978In its most recent audited fiscal period (FY2025, filed 2025-12-31), Schrodinger Inc. (SDGR) reported GAAP revenue of $255.9M (+23.3% vs. FY2024 revenue of $207.5M , and +18.1% cumulative change since FY2023) , GAAP net income of -$103.3M, operating cash flow of $13.9M, and free cash flow of $12.5M (+107.6% YoY). On the balance sheet, SDGR closed FY2025 with $726.2M in total assets against $0 in total debt (Altman Z-Score: 2.64, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $255.9M | -$103.3M | $13.9M | $12.5M | $726.2M | — |
| FY2024 (FY) | 2024-12-31 | $207.5M | -$187.1M | -$157.4M | -$164.7M | $823.2M | — |
| FY2023 (FY) | 2023-12-31 | $216.7M | $40.7M | -$136.7M | -$136.7M | — | — |
3. SDGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Schrodinger Inc. (NASDAQ: SDGR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $27.14 (-9.50% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SDGR ranks #231 in composite RQD confidence.
How does SDGR compare to MRVI and ZYME in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SDGR leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SDGR?
Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SDGR trading relative to its 50-day, 200-day, and 52-week technical levels?
SDGR last traded at $27.14 (-9.50% on volume of 1,947,789 shares), positioning the stock +7.15% above its 50-day simple moving average ($25.33) and +60.88% above its 200-day simple moving average ($16.87). Across its 52-week range of $10.94 to $33.78, SDGR sits at the 70.9% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($23.75 to $30.53).
SDGR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SDGR stock moving today?
Why SDGR Stock dropped -9.50% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 53/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SDGR — Schrodinger Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:18Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SDGR scores 56 out of 100 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine: 11 / 20. Per the RQD rating, this reflects ROIC of -35% and an FCF yield of 0.56%. For a prospective investor, this is the weakest-scoring pillar in terms of return generation: the company is not currently earning returns on invested capital, and the cash yield on the market value is minimal.
- Whale 13F Flow: 17 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning, and it is the strongest pillar. This suggests institutional interest that partially offsets the fundamental weakness, though the source data does not include the underlying 13F holder detail (see Analyst View section).
- Insider Conviction: 6 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider-driven conviction signals in the data.
- Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity considered. The mid-to-low score indicates the stock carries market-level risk without a distinct macro tailwind in the rating framework.
- Forensic Balance Sheet: 12 / 20. Per the RQD rating, Altman Z is 2.64, Piotroski F is 7/9, and Debt/Equity is 0.5. These readings are moderately supportive, reflecting a balance sheet that is not in distress on these measures but is not a standout.
Investor implications: The combined picture is a company with a meaningful institutional-flow signal and a reasonable forensic balance sheet, offset by negative returns on capital, negative operating and net margins, and a very low FCF yield. Upside drivers in the data are the institutional positioning and the balance sheet readings. Valuation tradeoffs are significant: with negative EPS and no reported P/E, traditional earnings-based valuation is not available in the source data, and the market is pricing the stock without an earnings anchor. The RQD verdict of "Trim" reflects the view that fundamental weakness outweighs the flow signals at current levels. This is an analytical summary, not personalized financial advice.
Business
Schrodinger Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Its market capitalization is $2.2B per the profile. The source data does not describe specific products, customers, or revenue model details beyond sector and industry classification.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $255.9M | $-166.9M | $-103.3M | N/A | $12.5M | $230.5M | N/A |
| FY 2024 | $207.5M | $-209.3M | $-187.1M | N/A | $-164.7M | $147.3M | N/A |
| FY 2023 | $216.7M | $-177.4M | $40.7M | N/A | $-136.7M | N/A | N/A |
Per the SEC financials, revenue rose from $207.5M in FY 2024 to $255.9M in FY 2025, while operating losses narrowed from $-209.3M to $-166.9M. Per the market data, gross margin is 55.7%, operating margin is -60%, and net margin is -40.4%, with ROIC at -35%. Per the RQD rating, the Altman Z-Score is 2.64 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.5. FY 2025 FCF turned positive at $12.5M after a $-164.7M outflow in FY 2024.
Recent Catalysts & News Wire Analysis
Per the recent news section, five items were reported:
- A Yahoo Finance report on a 7.6% share price surge, flagged as a CATALYST (GREEN).
- A StockInvest.us forecast piece, flagged as MARKET WIRE (YELLOW).
- A GuruFocus report noting the stock is down 11.3% but still overvalued with a GF Score of 71/100, flagged as MARKET WIRE (YELLOW).
- A Yahoo Finance report on fair value edging higher as analyst views split on AI growth, flagged as CATALYST (GREEN).
- A Stock Titan report on lithium-ion clustering in battery fluid, flagged as MARKET WIRE (YELLOW).
- A Simply Wall St report on analyst upgrades tied to the AI drug discovery story, flagged as CATALYST (GREEN).
Risk watch items: the GuruFocus headline's overvaluation framing and the split analyst views referenced in the news are the main caution points. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided source data. Not available in source data for detailed ripple analysis beyond sector classification (Health Care, Biotechnology: Pharmaceutical Preparations).
Open Questions
- What are the company's specific products, customers, and revenue drivers, given the source data provides only sector classification?
- What are the FY 2025 debt and EPS figures, which are recorded as N/A in the financials?
- What drove the swing from a $40.7M net income in FY 2023 to large losses in FY 2024 and FY 2025?
- What are the identities and sizes of the institutional holders underlying the 17/20 whale flow score?
- What analyst consensus and price targets exist, given analyst data is unavailable?
SDGR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Schrodinger Inc. (SDGR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 19h ago
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains? Yahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 22h ago
Schrodinger Stock Price Forecast. Should You Buy SDGR? StockInvest.us report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Schrodinger Inc (SDGR) Stock Down 11.3% but Still Overvalued -- GF Score: 71/100 GuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth Yahoo Finance report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Up to 40% of lithium ions in battery fluid cluster. This could help guide battery design. Stock Titan report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Is Schrödinger (SDGR) Fully Valued As Analyst Upgrades Back Its AI Drug Discovery Story? Simply Wall St report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
How Schrodinger Inc. (SDGR) Affects Rotational Strategy Timing Stock Traders Daily report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH GuruFocus • 1d ago
Schrodinger Inc (SDGR) Shares Fall 5.0% -- What GF Score of 72 T GuruFocus report covering Schrodinger Inc. (SDGR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SDGR Bull vs. Bear Conversation Board — What's Your Call at $27.14?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SDGR 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $32.39 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SDGR (D+ • RQD 56/100) a Buy at $29.99?
Welcome to the SDGR (Schrodinger Inc.) Roar Pit. Current RQD Composite is 56/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $22.49 (-25.0%)
Spot @ $29.99 Pump the brakes on SDGR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SDGR, but look at what you are paying: current EV/EBITDA multiples with 55.7% gross margins. Unless Schrodinger Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $35.39 (+18.0%)
Spot @ $29.99 SDGR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SDGR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $29.99 (52-wk range $10.94 - $33.78), any beat on forward guidance forces shorts and underweight funds to chase.